Financials
Financial year 2025
Worth noting
- More debts than assets in the latest financial year.
- A loss two years in a row.
- The team shrank two years in a row.
- Little cash and receivables against the short-term debts.
Gross margin
€ -2.1 million
▲ 42% vs 2024
Profit
Caution€ -3.2 million
▲ 32% vs 2024
Debts
High€ 8 million
▲ 58% vs 2024
Montis Biosciences from Leuven, company number BE0730979429, closed financial year 2025 with a result of € -3.2 million after tax. For that financial year Montis Biosciences recorded a gross margin of € -2.1 million and equity of € -5 million. Compared with financial year 2024, the result moved from € -4.7 million to € -3.2 million. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 1, 2026.
What happened at Montis Biosciences?
What happened at Montis Biosciences in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 3.2 million. Source: NBB ↗
- Detlev Biniszkiewicz stepped down as director. NBB
- Axxis V en C BV became a director. NBB
- Graeme Martin became a director. NBB
- Luc Dochez became a director. NBB
- Rana Al-Hallaq became a director. NBB
- New establishment in Leuven. KBO
- Ellie McGuire became a director. NBB
In short
From € 2.3 million loss in 2021 to € 3.2 million loss in 2025.
A new publication or filing at Montis Biosciences? We notify you, reason included.
Follow Montis BiosciencesNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
Behind Montis Biosciences are Ellie McGuire, Griet Vanpoucke, Rana Al-Hallaq, Luc Dochez, Graeme Martin and Axxis V en C BV. The same people are also behind NOVADIP BIOSCIENCES.
Directors
According to the 2025 annual accounts
Ellie McGuire
Director
since 2020
Griet Vanpoucke
Director
since 2019
Rana Al-Hallaq
Director
since 2020
Luc Dochez
Director
since 2020
Graeme Martin
Director
since 2021
since 2023
Detlev Biniszkiewicz
Director
since 2020 · until 2025
Establishments
Establishment units
Physical locations of this company
Gaston Geenslaan 3
3001 Leuven
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 11 companies are registered at this address.
QUOMAK
€ 4.6 million gross margin · 2025
Metaptys
€ 1.3 million gross margin · 2025
Perseus Biomics
€ 320,026 gross margin · 2025
ReWind Therapeutics
€ -528,262 gross margin · 2025
AUGUSTINE THERAPEUTICS
€ -1.7 million gross margin · 2025
+6 more
Details
- Company number
- 0730.979.429
- VAT number
- BE 0730.979.429
- Registered office
- Gaston Geenslaan 3, 3001 Leuven
- Names & denominations
- Montis Biosciences
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 24 July 2019
- Peppol
- Active · Active since 20 Aug 2025
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied